2012:

Ivanova M, Lamprecht C, Loureiro MJ, Huzil T, Foldvari M. (2012) Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. International Journal of Nanomedicine 7: 403-415.

2011:

Huzil T, Sivaloganathan S, Kohandel M , Foldvari M. (2011) Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3: 449–462.

Lamprecht C, Huzil T, Ivanova M, Foldvari M. (2011) Non-Covalent Functionalization of Carbon Nanotubes with Surfactants for Pharmaceutical Applications A Critical Mini-Review. Drug Delivery Letters 1:45-57.

Badea I, Shaterian, N. , Foldvari M. (2011) Topical Gene Delivery in Mice Using Gemini Surfactant - Lipid Nanoparticles With and Without Tape Electrode Electroporation. Drug Delivery Letters 1:62-66.

Badea I, Virtanen C, Verrall RE, Rosenberg A and Foldvari M. (2011) Effect of topical interferon-γ gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice. Gene Therapy doi:10.1038.

Foldvari M, Elsabahy M. (2011) Editorial Hot Topic: Nanotechnology Enables Superior Medical Therapies. Current Drug Delivery 8:225-226.

Elsabahy M, Nazarali A, Foldvari M. (2011) Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions. Current Drug Delivery 8:235-244.

Singh J, Yang P, Michel D, Verrall RE, Foldvari M, Badea I. (2011) Amino Acid-Substituted Gemini Surfactant-Based Nanoparticles as Safe and Versatile Gene Delivery Agents. Current Drug Delivery 8:299-306.

Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah Z, Gaspar K, Hull P, Shear NH. (2011) Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Current Drug Delivery 8:307-319.

2010:

Donkuru M, Badea I, Wettig SD, Verrall RE, Elsabahy M, Foldvari M. (2010) Advancing non-viral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Future Medicine) 5:1103-1127.

Yang P, Singh J, Wettig SD, Foldvari M, Verrall RE, Badea I. (2010) Enhanced gene expression in epithelial cells transfected with amino-acid substituted gemini nanoparticles. Eur J Pharm Biopharm 75:311-320.

Foldvari M. (2010) Formulating nanomedicines: focus on carbon nanotubes as novel nanoexcipients. Key Eng Mat 441:53-74.

Foldvari M, Badea I, Wettig SD, Baboolal D, Kumar P, Creagh AL, Haynes CA. (2010) Topical delivery of interpheron alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol Pharmaceutics 7:751-762.

2009:

Badea I, Babiuk S, Babiuk L, Foldvari M. (2009) Gemini nanoparticles as co-delivery systems for antigen-CpG oligodeoxynucleotide adjuvant combination. Int J Biomed Nanosci Nanotech1:290-307.

Badea I, Taylor M, Rosenberg A, Foldvari M. (2009) Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheomatology 48:213-221.

Taghavi A, Allan B, Mutviri G, Foldvari M, Van Kessel A, Willson P, Babiuk L, Potter A, Gomis S. (2009) Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Del 6:76-82.

Kumar P, Batta R, LaBine G, Shen J, Gaspar K, Docherty J, Foldvari M. (2009) Stabilization of interpheron alpha-2b in a topical cream. Pharm Technol 33:80-86.

2008:

Foldvari M, Bagonluri M. (2008) Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine 4:173-182.

Foldvari M, Bagonluri M. (2008) Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine 4:183-200.

Wettig SD, Badea I, Verrall RE, Foldvari M. (2008) Gemini surfactants: A new family of building blocks for cationic lipid-mediated DNA delivery. Curr Drug Ther 8:9-23.

2007:

Wettig SD, Badea I, Donkuru, M, Verrall RE, Foldvari M. (2007) Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles. J Gene Med 9:649-658.

Wang C, Li X, Wettig SD, Badea I, Foldvari M, Verrall RE. (2007) Investigation of complexes formed by interaction of cationic gemini surfactants with deoxyribonucleic acid. Phys Chem Chem Phys 9:1616-1628.

Wettig SD, Wang C, Verrall RE, Foldvari M. (2007) Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys Chem Chem Phys 9:871-877 (appears on front cover).

Wang C, Wettig SD, Foldvari M, Verrall RE. (2007) Synthesis, characterization and use of asymmetric pyrenyl-gemini surfactants as emissive components in DNA-lipoplex systems. Langmuir 23:8995-9001.

Badea I, Wettig SD, Verrall RE, Foldvari M. (2007) Topical non-invasive gene delivery using gemini nanoparticles in interferon-γ-deficient mice. Eur J Pharm Biopharm 65:414-422.

2006:

Foldvari M, Wettig SD, Badea I, Verrall RE, Bagonluri M. (2006) Dicationic gemini surfactant gene delivery complexes contain cubic-lamellar mixed polymorphic phase. Nanotech 2:400-403.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006) Biphasic lipid vesicles as subcutaneous delivery systems for protein antigens and CpG oligonucleotides. Curr Drug Del 3:129-135.

Foldvari M. (2006) Topical non-invasive delivery technologies for the delivery of genetic material. (Editorial) Curr Drug Deliv 3:1.

Foldvari M, Babiuk S, and Badea I. (2006) DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv 3:17-28.

Wei C, Lyubchenko YL, Ghandehari H, Hanes J, Stebe KJ, Mao HQ, Haynie DT, Tomalia DA, Foldvari M, Monteiro-Riviere N, Simeonova P, Nie S, Mori H, Gilbert S, Needham D. (2006) New technology and clinical applications of nanomedicine: Highlights of the Second Annual Meeting of the American Academy of Nanomedicine (Part I). Nanomedicine 2:253-263.

Cui Z, Dierling A, Foldvari M. (2006) Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv 3:29-35.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006). Biphasic lipid vesicles as subcutaneous delivery systems for protein antigens and CpG oligonucleotides. Curr Drug Del 3:129-135.

Foldvari M, Kumar P, King M, Batta R, Michel D, Badea I, Wloch M. (2006) Gene delivery into human skin in vitro using biphasic lipid vesicles. Curr Drug Deliv 3:89-96.

Foldvari M, Badea I, Wettig SD, Verrall RE, Bagonluri M. (2006) Structural characterization of novel gemini non-viral DNA delivery systems for cutaneous gene therapy. J Exp Nanosci 1:165-176.

2005:

Foldvari M, Badea I, Wettig S, Verrall R, Bagonluri M. (2005) Structural characterization of novel micro- and nano-scale non-viral DNA delivery systems for cutaneous gene therapy. Nanotech 1:128-131.

Alcón V, Baca-Estrada M, Vega-López M, Willson P, Babiuk LA, Kumar P, Hecker R,

Foldvari M. (2005). Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS Journal 7(3) Article 57:E566-571.

Alcón VL, Baca-Estrada M, Vega-López MA, Willson P, Babiuk LA, Kumar P, Foldvari M. (2005). Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. J Pharm Pharmacol 57:955-962.

Alcón V, Baca-Estrada M, Vega-López M, Willson P, Babiuk LA, Kumar P, Hecker R,

Foldvari M. (2005). Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS Journal 7(3) Article 57:E566-571.

Badea I, Verrall R, Baca-Estrada M, Tikoo S, Rosenberg A, Kumar P, Foldvari M.

(2005) In vivo cutaneous interferon-γ gene delivery using novel dicationic (gemini) surfactant–plasmid complexes. J Gene Med 7:1200-1214.

Li X, Wettig SD, Wang C, Foldvari M, Verrall RE. (2005) Synthesis and solution properties of gemini surfactants containing oleyl chains. Phys Chem Chem Phys 7:3172-3178.

2004:

Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. (2004). Biphasic lipid vesicles (Biphasix™) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv 1:9-15.

2003:

Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L. (2003). Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther 8:992-998.

Alcón VL, Foldvari M, Snider M, Willson P, Gomis S, Hecker R, Babiuk LA, Baca-Estrada ME. (2003). Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix™). Vaccine 21:1811-1814.

King MJ, Michel D, Foldvari M. (2003) Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol 55:1339-1344.

2002:

Jaafari MR, Foldvari M. (2002). Targeting of liposomes to human keratinocytes through adhesive peptides from immunoglobulin domains in the presence of IFN-gamma. Drug Deliv 9:1-9.

Jaafari MR, Foldvari M. (2002). Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains. J Pharm Sci 91:396-404.

Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. (2002). The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107:69-76.

Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. (2002) Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol 54:1609-1614.

Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. (2002) Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20:3399-3408.

King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. (2002). Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 4:479-88.

2000:

Foldvari M. (2000). Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm Sci Tech Today 3:417-425.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). Vaccine delivery: lipid-based delivery systems. J Biotechnol 83:91-104.

Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.

Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. (2000). Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18:2203-2211.

Papp Z, Middleton DM, Rontved CM, Foldvari M, Gordon JR, Baca-Estrada ME. (2000). Transtracheal administration of interleukin-12 induces neutrophil responses in the murine lung. J Interferon Cytokine Res 20:191-196.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. (2000). Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18:1847-1854.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). Vaccine delivery: lipid-based delivery systems. J Biotechnol 83:91-104.

1999:

Jaafari MR, Foldvari M. (1999). P0 protein mediated targeting of liposomes to melanoma cells with high level of ICAM-1 expression. J Drug Target 7:101-112.

Foldvari M. (1999) Novel delivery systems for biotechnology drugs: Recent progress toward improved therapies. Can J Clin Pharmacol 6:65-66.

Baca-Estrada ME, Foldvari M, Snider M. (1999). Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res 19:455-462.

Babiuk LA, Lewis J, Suradhat S, Baca-Estrada M, Foldvari M, Babiuk S. (1999) Polynucleotide vaccines: potential for inducing immunity in animals. J Biotechnol 73: 131-140.

Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M. (1999). Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol Appl Biochem 30 (Pt 2):129-37.

1998:

Foldvari M, Jaafari MR, Mezei M, Mezei C. (1998) Targeting liposomes through immunoglobulin superfamily domains: Po protein as model. Drug Deliv 5:183-195.

Foldvari M. (1998) Liposomal delivery systems in modern medicine. Drugs (Gyogyszereink) 48:162-171.

Foldvari M, Attah-Poku S, Hu J, Li Q, Hughes H, Babiuk LA, Kruger S. (1998). Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery. J Pharm Sci 87:1203-1208.

1997:

Baca-Estrada ME, Foldvari M, Snider M, van Drunen Littel-van den Hurk S, Babiuk LA. (1997). Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. Vaccine 15:1753-1760.

1996:

Foldvari M. (1996) Effect of vehicle on topical liposomal drug delivery: petrolatum bases. J Microencapsul 13:589-600.

Selected Research Papers

2012:

2011: